Article Per Year (5 Year)
p-Index From 2021 - 2026
0.408
P-Index
This Author published in this journals
All Journal Bioscientia Medicina : Journal of Biomedicine and Translational Research Bioscientia Medicina : Journal of Biomedicine and Translational Research
Widyanti Soewoto
Department of Surgical Oncology, Faculty of Medicine, Universitas Sebelas Maret/Dr. Moewardi Regional General Hospital, Surakarta, Indonesia
Biochemistry, Genetics & Molecular Biology Immunology & microbiology Medicine & Pharmacology Neuroscience

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
Beyond PD-1/PD-L1: A Systematic Review and Meta-Analysis of LAG-3, TIGIT, and TIM-3 as Prognostic Biomarkers and Therapeutic Targets in Breast Cancer Dinar Kukuh Prasetyo; Widyanti Soewoto
Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 10 No. 6 (2026): Bioscientia Medicina: Journal of Biomedicine & Translational Research
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/bsm.v10i6.1600

Abstract

Background: The therapeutic paradigm for breast cancer advanced significantly with programmed cell death-1 (PD-1) and programmed cell death ligand-1 (PD-L1) inhibitors. However, adaptive immune resistance, driven by compensatory upregulation of alternative checkpoints—Lymphocyte-activation gene 3 (LAG-3), T-cell immunoreceptor with Ig and ITIM domains (TIGIT), and T-cell immunoglobulin and mucin-domain containing-3 (TIM-3)—limits durable responses. This study aimed to quantitatively synthesize the prognostic significance, tumor microenvironment interactions, and translational surgical implications of these biomarkers in breast cancer. Methods: A systematic literature search (PubMed, Embase, Cochrane) identified original research evaluating LAG-3, TIGIT, and TIM-3 expression in breast cancer cohorts. Data extraction focused on overall survival (OS) hazard ratios (HR), standardized mean differences (SMD) for tumor-infiltrating lymphocyte (TIL) density, and pathological complete response (pCR) rates. Random-effects meta-analyses generated forest plots, assessed heterogeneity (I-squared), and evaluated publication bias via funnel plots. Results: Eight major cohorts comprising over 7,200 patients were included. High LAG-3 expression on TILs in triple-negative breast cancer (TNBC) was significantly associated with improved OS (Pooled HR 0.88, 95% CI 0.81-0.95, p=0.002) and higher pCR rates following neoadjuvant chemotherapy. Conversely, elevated TIGIT expression in primary tumors correlated with poorer OS (Pooled HR 1.58, 95% CI 1.18-2.11, p=0.004) and increased locoregional recurrence risk. TIM-3 demonstrated dual prognostic value: favorable in basal-like subtypes but detrimental in luminal subtypes. Funnel plots indicated minimal publication bias. Conclusion: LAG-3, TIGIT, and TIM-3 function as distinct, non-redundant biomarkers. LAG-3 signifies a primed, actionable immune response, whereas TIGIT and TIM-3 indicate severe immune exhaustion. Mapping these profiles provides critical translational value for optimizing personalized surgical timing, predicting neoadjuvant downstaging, and selecting adjuvant immunotherapies.
Beyond PD-1/PD-L1: A Systematic Review and Meta-Analysis of LAG-3, TIGIT, and TIM-3 as Prognostic Biomarkers and Therapeutic Targets in Breast Cancer Dinar Kukuh Prasetyo; Widyanti Soewoto
Bioscientia Medicina : Journal of Biomedicine and Translational Research Vol. 10 No. 6 (2026): Bioscientia Medicina: Journal of Biomedicine & Translational Research
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/bsm.v10i6.1600

Abstract

Background: The therapeutic paradigm for breast cancer advanced significantly with programmed cell death-1 (PD-1) and programmed cell death ligand-1 (PD-L1) inhibitors. However, adaptive immune resistance, driven by compensatory upregulation of alternative checkpoints—Lymphocyte-activation gene 3 (LAG-3), T-cell immunoreceptor with Ig and ITIM domains (TIGIT), and T-cell immunoglobulin and mucin-domain containing-3 (TIM-3)—limits durable responses. This study aimed to quantitatively synthesize the prognostic significance, tumor microenvironment interactions, and translational surgical implications of these biomarkers in breast cancer. Methods: A systematic literature search (PubMed, Embase, Cochrane) identified original research evaluating LAG-3, TIGIT, and TIM-3 expression in breast cancer cohorts. Data extraction focused on overall survival (OS) hazard ratios (HR), standardized mean differences (SMD) for tumor-infiltrating lymphocyte (TIL) density, and pathological complete response (pCR) rates. Random-effects meta-analyses generated forest plots, assessed heterogeneity (I-squared), and evaluated publication bias via funnel plots. Results: Eight major cohorts comprising over 7,200 patients were included. High LAG-3 expression on TILs in triple-negative breast cancer (TNBC) was significantly associated with improved OS (Pooled HR 0.88, 95% CI 0.81-0.95, p=0.002) and higher pCR rates following neoadjuvant chemotherapy. Conversely, elevated TIGIT expression in primary tumors correlated with poorer OS (Pooled HR 1.58, 95% CI 1.18-2.11, p=0.004) and increased locoregional recurrence risk. TIM-3 demonstrated dual prognostic value: favorable in basal-like subtypes but detrimental in luminal subtypes. Funnel plots indicated minimal publication bias. Conclusion: LAG-3, TIGIT, and TIM-3 function as distinct, non-redundant biomarkers. LAG-3 signifies a primed, actionable immune response, whereas TIGIT and TIM-3 indicate severe immune exhaustion. Mapping these profiles provides critical translational value for optimizing personalized surgical timing, predicting neoadjuvant downstaging, and selecting adjuvant immunotherapies.
Co-Authors Dinar Kukuh Prasetyo